.-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018.
.: "targeted cgrp small molecule antagonists for acute migraine therapy."
.
.
harvard medical school: "cgrp: a new era for migraine treatment."
.